Humoral responses to melanoma vaccine, genetically modified with interleukin 6 and soluble interleukin 6 receptor.
Nawrocki
S
S
GreatPoland Cancer Centre, Garbary 15, Poznań, Poland.
Łaciak
M
M
Izycki
D
D
Gryska
K
K
Wysocki
P J
PJ
Grabarczyk
P
P
Karczewska
A
A
Kaczmarek
A
A
Murawa
P
P
Malicki
J
J
Rose-John
S
S
Mackiewicz
A
A
D000328:Adult; D000912:Antibodies, Neoplasm / Q000096:biosynthesis; D000951:Antigens, Neoplasm / Q000235:genetics; D001324:Autoantigens / Q000235:genetics; D019496:Cancer Vaccines / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000235:genetics / Q000378:metabolism*; D007519:Isoantigens / Q000235:genetics; D008297:Male; D008545:Melanoma / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D058950:Melanoma-Specific Antigens; D008875:Middle Aged; D014442:Monophenol Monooxygenase / Q000235:genetics; D009363:Neoplasm Proteins / Q000235:genetics; D011379:Prognosis; D019947:Receptors, Interleukin-6 / Q000096:biosynthesis* / Q000235:genetics; D012995:Solubility
D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D001324:Autoantigens; D019496:Cancer Vaccines; D015850:Interleukin-6; D007519:Isoantigens; C072011:MAGEA1 protein, human; C072013:MAGEA3 protein, human; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins; D019947:Receptors, Interleukin-6; D014442:Monophenol Monooxygenase